Clinical trial
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients…
NCT00070382 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00070382 |
|---|---|
| Title | Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer |
| Official title | A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | darbepoetin alfa, epoetin alfa |
| Enrollment | 14 |
| Start date | Aug 1, 2003 |
| Primary completion | Nov 1, 2003 |
| First posted | Oct 7, 2003 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: